Hypothalamic GIPR signaling is not required for the additive effects of GIPR and GLP-1R agonism in inducing weight loss, and the GIP receptor is expressed by several cells in the hypothalamus and brainstem that can extinguish appetite
When the Breakthrough Obesity G-Agonist Drugs Exceed Expectations The expanding GLP-1 family of drugs and their expanded potential use cases Back last December I wrote about the The New Obesity Breakthrough Drugs, and specifically the striking results in randomized trials for semaglutide (Wegovy) and tirzepatide (Mounjaro) for weight loss, their putative mechanism(s), while also emphasizing their very high cost, lack of plan for successful weaning, and exacerbation of health inequities
Calixto-Tlacomulco, S
Peter Emmrich Dipl.-Biologe, Chemiker und Bestsellerautor In meiner Praxis sehe ich tglich, wie stark Ernhrung und Lebensstil unsere Gesundheit beeinflussen
Ferreira FRT, do Couto LM, Saporetti CM (2025a) Using deep learning applied in computer vision for the inclusion of individuals with tetraplegia through assistive robotics via facial features
FAQ Does Ozempic make oxycodone less effective
